A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

February 14, 2025

Study Completion Date

February 14, 2025

Conditions

Heterozygous Familial HypercholesterolemiaAtherosclerotic Cardiovascular DiseaseHypercholesterolemia

Interventions

DRUG

VERVE-101

Intravenous (IV) infusion.

Trial Locations (3)

Clinical Study Center, Auckland

Clinical Study Center, Christchurch

Clinical Study Center, London

All Listed Sponsors

lead

Verve Therapeutics, Inc.

INDUSTRY